Navigation Links
Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
Date:7/27/2009

New York, NY The Lymphoma Research Foundation (LRF) is pleased to announce that the 2009 Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation Clinical Investigator Career Development Award has been awarded to Kai Fu, MD, PhD, Associate Professor at the Nebraska Medical Center in Omaha, Nebraska.

Lymphoma, the most common type of blood cancer, is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). According to a 2008 report from the World Health Organization, there are six types of HL and over 61 types of NHL; many of which are rare diseases.

A member of LRF's Mantle Cell Lymphoma Consortium (MCLC), Dr. Fu's work will focus on mantle cell lymphoma (MCL), an aggressive malignant B-cell form of non-Hodgkin lymphoma (NHL). Mantle cell lymphoma is a rare form of NHL accounting for 6 percent of all new diagnoses of NHL or approximately 3,000 new cases per year in the United States. Mantle cell usually affects men over 60 and is frequently diagnosed as a Stage IV disease, often present in lymph nodes above and below the diaphragm and in most cases involves the gastrointestinal tract and bone marrow.

MCL is characterized by over expression of the gene cyclin D1 due to a chromosomal translocation. A subset of MCL also expresses higher levels of a group of small RNA molecules, called miR-17~92. Dr. Fu and his co-workers have found that higher expression of miR-17~92 is directly correlated with poorer patient survival. These findings indicate that higher miR-17~92 expression induces abnormal activation of a pathway in tumor cells that leads to increased resistance to standard chemotherapy. Dr. Fu will conduct a pre-clinical study to determine whether suppression of miR-17~92 will improve the effect of chemotherapy. His study will thus provide a novel approach to treating MCL patients.

"Dr. Fu's elegant proposal explores a new avenue for understanding MCL and identifying potential therapeutic targets. We are delighted that Dr. Fu has chosen MCL as the focus of his Clinical Career Development Project," stated Michael Williams, MD, Director, Hematologic Malignancy Program - University of Virginia and Chair of LRF's Mantle Cell Consortium

The 3-year Clinical Investigator Career Development Award is designed to fund training of clinicians who will participate in developing new therapeutics and diagnostic tools for lymphoma.

The focus of the training is to prepare clinicians to design and administer clinical studies in lymphoma and to take on the primary responsibilities for clinical trial design, protocol writing, Institutional Review Board (IRB) submission, and publication. Dr. Fu will be pursuing a Career Development Plan with the guidance of his mentor, Dr. Wing Chan, Co-Director, Center for Lymphoma and Leukemia Research, at the University of Nebraska Medical Center, Omaha, NE. Dr. Fu will be supported by a grant of $300K over 3 years to accomplish his research project. The LRF thanks Millennium Pharmaceuticals, Inc./The Takeda Oncology Company for their generous support of this grant.

"We are proud to be able to support lymphoma research through grants such as this one, and we are hopeful that the work we support may someday be a significant contribution to the discovery of new methods for treating blood cancer," said Dixie-Lee Esseltine, M.D., Vice President, Global Medical Affairs, Millennium.


'/>"/>

Contact: Marion F. Swan
mswan@lymphoma.org
212-349-6435
Lymphoma Research Foundation
Source:Eurekalert

Related medicine news :

1. Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments
2. Armed Forces Retirement Home Selects Millenniums Pharmacy Services
3. Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
4. Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
5. Industry Veteran Stephen Duvall Joins Millennium Management Team
6. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
7. Millennium Research Groups New Perception Pulse Product Offers Clients an Innovative New Customer Behavior and Loyalty Tracking Tool
8. Although the Health Care Market is Recession-Resistant, It Is Not Recession-Immune, According to Millennium Research Groups Medtech Economic Quarterly Publication
9. US Spinal Nonfusion Procedures Set to Increase Nearly Five Times From 2008 to 2013, According to Millennium Research Group
10. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
11. Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: